Ocular Therapeutix (OCUL) opened 2026 with Q1 numbers that keep attention squarely on growth versus profitability, with trailing twelve month revenue at US$52 million and a loss of US$266 million translating into a Basic EPS of US$1.42 loss. Over the past six reported quarters, quarterly revenue has ranged from US$10.7 million to US$17.1 million while quarterly Basic EPS moved between US$0.22 and US$0.39 loss, underscoring a business that is building its top line but still carrying heavy losses. For investors, the key question from this earnings release is whether that revenue base and the forecast 48.6% revenue growth can eventually support healthier margins and a path toward more efficient use of capital.

See our full analysis for Ocular Therapeutix.

With the headline numbers on the table, the next step is to see how these results line up with the prevailing stories about Ocular Therapeutix. This highlights where the growth narrative matches the data and where the margin picture raises tougher questions.

Losses stay heavy at US$265.9 million over the last year

• Over the latest trailing twelve months, Ocular Therapeutix recorded a net loss of US$265.9 million on US$52.0 million of revenue, which means the business is still spending a lot more than it is bringing in from product sales.
• Consensus narrative highlights a path where revenue is expected to grow quickly, with analysts talking about growth rates between roughly 32.6% and 76.8% a year. However, the historical pattern of widening losses over about five years, at around 27% per year, makes it clear that higher sales on their own have not yet translated into earnings.

High P/S of 40.9x versus 5.3x industry average

• The stock is trading on a P/S of 40.9x, compared with a peer average of 1.7x and a wider US Pharmaceuticals industry average of 5.3x, so each dollar of Ocular Therapeutix revenue is priced much higher than revenue at many other drug companies.
• Bulls often argue that strong forecast revenue growth of about 48.6% a year and the focus on therapies for retinal diseases could justify paying a rich multiple. Yet the current losses of US$265.9 million over the last year and the expectation that the company remains unprofitable over the next three years mean that growth needs to work hard to support this kind of premium valuation.
• Consensus narrative ties that growth story to analyst expectations of future annual revenue expansion of up to 76.8%, but those same expectations still assume no profitability within three years.
• With shares at US$9.71 against a consensus target of US$26.00, believers in the bullish view are leaning on those growth and pipeline assumptions more than on any current earnings strength.

Bulls who see fast growth and pipeline potential as reasons for the premium valuation may want to compare that story with the detailed bull case on Ocular Therapeutix, including how trial outcomes and revenue assumptions feed into future earnings and pricing power. 🐂 Ocular Therapeutix Bull Case

Dilution risk and bearish worries on cash burn

• Shareholders have already experienced substantial dilution over the past year, and analysts also expect the share count to grow by about 7% per year over the next three years, which can make it harder for per share metrics to improve even if total revenue rises.
• Bears focus on this dilution, the continuing losses and the fact that Ocular Therapeutix is not forecast to be profitable within three years, arguing that high cash use and reliance on equity funding could weigh on long term returns for existing holders even if revenue tracks the forecast 48.6% a year.
• Those concerns line up with the recent record of trailing twelve month losses that have stayed above US$190 million over the last several reported periods, despite revenue in the US$52.0 million to US$63.7 million range.
• At the same time, the cited DCF fair value of US$14.90 sits above the current US$9.71 share price, so investors comparing the bearish view with this DCF figure are weighing dilution and loss trends against a model that points to upside relative to that fair value.

Skeptical investors who worry about dilution and ongoing losses can walk through the detailed bear case on Ocular Therapeutix to see how those risks stack up against the current share price and funding needs. 🐻 Ocular Therapeutix Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Ocular Therapeutix on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Mixed on the story so far and want to test the headlines against the numbers yourself? Take a closer look at the balance of risks and rewards with these 2 key rewards and 4 important warning signs 2 key rewards and 4 important warning signs

See What Else Is Out There

Ocular Therapeutix pairs heavy losses of US$265.9 million, ongoing dilution and no near term profitability expectations with a high P/S multiple that prices in a lot of optimism.

If you want ideas where the balance of risk and reward may look more resilient, check stocks screened for stronger financial footing and steadier fundamentals through the solid balance sheet and fundamentals stocks screener (45 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.